Emerging drugs for alopecia areata: JAK inhibitors

Matilde Iorizzo, Antonella Tosti

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Introduction: Alopecia Areata is a common form of non-scarring hair loss that usually starts abruptly with a very high psychological impact. Due to the still not completely understood etiopathogenesis, at present there is no treatment that can induce a permanent remission and there is no drug approved for the treatment of this disorder. Areas covered: Leading existing treatment are briefly overviewed and then ongoing research on Janus Kinases Inhibitors is discussed, reviewing trials with oral and topical formulations so as new opportunities for other forms of alopecia, such as cicatricial alopecia. Expert opinion: JAK inhibitors represent a promise among alopecia treatments, but further studies are needed on long term safety. There is still no validated dosage for alopecia areata and the vehicles used for topical formulations seem not yet ideal in terms of skin penetration and reduced systemic absorption. Hopefully several studies are ongoing and we hope, in the near future, that JAK inhibitors will become part of the armamentarium to treat alopecia areata patients in terms of safety and costs.

Original languageEnglish (US)
Pages (from-to)77-81
Number of pages5
JournalExpert Opinion on Emerging Drugs
Volume23
Issue number1
DOIs
StatePublished - Jan 2 2018

Fingerprint

Alopecia Areata
Alopecia
Pharmaceutical Preparations
Janus Kinases
Safety
Expert Testimony
Therapeutics
Psychology
Costs and Cost Analysis
Skin
Research

Keywords

  • Alopecia
  • alopecia areata
  • baricitinib
  • cicatricial alopecia
  • JAK inhibitors
  • ruxolitinib
  • tofacitinib
  • treatment

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Emerging drugs for alopecia areata : JAK inhibitors. / Iorizzo, Matilde; Tosti, Antonella.

In: Expert Opinion on Emerging Drugs, Vol. 23, No. 1, 02.01.2018, p. 77-81.

Research output: Contribution to journalReview article

@article{14558b80fe244a1d973c6f22c721e9be,
title = "Emerging drugs for alopecia areata: JAK inhibitors",
abstract = "Introduction: Alopecia Areata is a common form of non-scarring hair loss that usually starts abruptly with a very high psychological impact. Due to the still not completely understood etiopathogenesis, at present there is no treatment that can induce a permanent remission and there is no drug approved for the treatment of this disorder. Areas covered: Leading existing treatment are briefly overviewed and then ongoing research on Janus Kinases Inhibitors is discussed, reviewing trials with oral and topical formulations so as new opportunities for other forms of alopecia, such as cicatricial alopecia. Expert opinion: JAK inhibitors represent a promise among alopecia treatments, but further studies are needed on long term safety. There is still no validated dosage for alopecia areata and the vehicles used for topical formulations seem not yet ideal in terms of skin penetration and reduced systemic absorption. Hopefully several studies are ongoing and we hope, in the near future, that JAK inhibitors will become part of the armamentarium to treat alopecia areata patients in terms of safety and costs.",
keywords = "Alopecia, alopecia areata, baricitinib, cicatricial alopecia, JAK inhibitors, ruxolitinib, tofacitinib, treatment",
author = "Matilde Iorizzo and Antonella Tosti",
year = "2018",
month = "1",
day = "2",
doi = "10.1080/14728214.2018.1444750",
language = "English (US)",
volume = "23",
pages = "77--81",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Emerging drugs for alopecia areata

T2 - JAK inhibitors

AU - Iorizzo, Matilde

AU - Tosti, Antonella

PY - 2018/1/2

Y1 - 2018/1/2

N2 - Introduction: Alopecia Areata is a common form of non-scarring hair loss that usually starts abruptly with a very high psychological impact. Due to the still not completely understood etiopathogenesis, at present there is no treatment that can induce a permanent remission and there is no drug approved for the treatment of this disorder. Areas covered: Leading existing treatment are briefly overviewed and then ongoing research on Janus Kinases Inhibitors is discussed, reviewing trials with oral and topical formulations so as new opportunities for other forms of alopecia, such as cicatricial alopecia. Expert opinion: JAK inhibitors represent a promise among alopecia treatments, but further studies are needed on long term safety. There is still no validated dosage for alopecia areata and the vehicles used for topical formulations seem not yet ideal in terms of skin penetration and reduced systemic absorption. Hopefully several studies are ongoing and we hope, in the near future, that JAK inhibitors will become part of the armamentarium to treat alopecia areata patients in terms of safety and costs.

AB - Introduction: Alopecia Areata is a common form of non-scarring hair loss that usually starts abruptly with a very high psychological impact. Due to the still not completely understood etiopathogenesis, at present there is no treatment that can induce a permanent remission and there is no drug approved for the treatment of this disorder. Areas covered: Leading existing treatment are briefly overviewed and then ongoing research on Janus Kinases Inhibitors is discussed, reviewing trials with oral and topical formulations so as new opportunities for other forms of alopecia, such as cicatricial alopecia. Expert opinion: JAK inhibitors represent a promise among alopecia treatments, but further studies are needed on long term safety. There is still no validated dosage for alopecia areata and the vehicles used for topical formulations seem not yet ideal in terms of skin penetration and reduced systemic absorption. Hopefully several studies are ongoing and we hope, in the near future, that JAK inhibitors will become part of the armamentarium to treat alopecia areata patients in terms of safety and costs.

KW - Alopecia

KW - alopecia areata

KW - baricitinib

KW - cicatricial alopecia

KW - JAK inhibitors

KW - ruxolitinib

KW - tofacitinib

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85044005855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044005855&partnerID=8YFLogxK

U2 - 10.1080/14728214.2018.1444750

DO - 10.1080/14728214.2018.1444750

M3 - Review article

C2 - 29466675

AN - SCOPUS:85044005855

VL - 23

SP - 77

EP - 81

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 1

ER -